NCT00152958View on ClinicalTrials.gov

A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)

PHASE3CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

February 28, 2005

Conditions
Restless Legs Syndrome
Interventions
DRUG

Pramipexole

Trial Locations (12)

Unknown

Boehringer Ingelheim Investigational Site, Berlin

Charité Campus Virchow-Klinikum, Berlin

emovis GmbH, Berlin

Boehringer Ingelheim Investigational Site, Chemnitz

ClinPharm Internat. GmbH & Co. KG, Görlitz

Clinpharm International GmbH & Co. KG, Hellersdorf

Paracelsus-Elena-Klinik, Kassel

ClinPharm International GmbH & Co. KG, Leipzig

Neurologische Klinik der Otto-von-Guericke-Universität, Magdeburg

Universitätsklinikum Giessen und Marburg, Marburg

Boehringer Ingelheim Investigational Site, München

Boehringer Ingelheim Investigational Site, Würzburg

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00152958 - A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.) | Biotech Hunter | Biotech Hunter